These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 18425336

  • 21. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
    Caronia D, Patiño-García A, Milne RL, Zalacain-Díez M, Pita G, Alonso MR, Moreno LT, Sierrasesumaga-Ariznabarreta L, Benítez J, González-Neira A.
    Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
    [Abstract] [Full Text] [Related]

  • 22. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
    Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, Lordick F, Hois S, Plaschke S, Höfler H, Keller G.
    Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
    [Abstract] [Full Text] [Related]

  • 23. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [Abstract] [Full Text] [Related]

  • 24. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH, Hua D, Du X.
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [Abstract] [Full Text] [Related]

  • 25. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P.
    Clin Cancer Res; 2007 Jul 01; 13(13):3855-9. PubMed ID: 17606717
    [Abstract] [Full Text] [Related]

  • 26. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May 01; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 27. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
    Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, Sun T, Zhao D, Yang M, Liu J, Xu B, Lin D.
    Clin Cancer Res; 2008 May 01; 14(9):2878-86. PubMed ID: 18451256
    [Abstract] [Full Text] [Related]

  • 28. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R.
    J Clin Oncol; 2007 Jul 01; 25(19):2747-54. PubMed ID: 17602080
    [Abstract] [Full Text] [Related]

  • 29. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.
    Lung Cancer; 2008 Oct 01; 62(1):105-12. PubMed ID: 18395930
    [Abstract] [Full Text] [Related]

  • 30. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M.
    Endocr Relat Cancer; 2009 Sep 01; 16(3):907-18. PubMed ID: 19240185
    [Abstract] [Full Text] [Related]

  • 31. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
    Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, Wain JC, Neuberg D, Liu G, Christiani DC.
    Clin Cancer Res; 2005 Feb 15; 11(4):1534-8. PubMed ID: 15746057
    [Abstract] [Full Text] [Related]

  • 32. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
    Sereno M, Cejas P, Moreno V, Belda-Iniesta C, López R, Nistal M, Feliu J, De Castro Carpeño J.
    Int J Oncol; 2012 Jun 15; 40(6):2104-10. PubMed ID: 22344449
    [Abstract] [Full Text] [Related]

  • 33. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.
    Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, Bisonni R, Canestrari E, Ficarelli R, Menichetti ET, Mari D, Testa E, Silva R, Vincenzi B, Giordani P, Cascinu S, Giustini L, Tonini G, Magnani M.
    J Clin Oncol; 2006 Apr 20; 24(12):1883-91. PubMed ID: 16622263
    [Abstract] [Full Text] [Related]

  • 34. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
    Ozcan MF, Dizdar O, Dincer N, Balcı S, Guler G, Gok B, Pektas G, Seker MM, Aksoy S, Arslan C, Yalcin S, Balbay MD.
    Urol Oncol; 2013 Nov 20; 31(8):1709-15. PubMed ID: 22863869
    [Abstract] [Full Text] [Related]

  • 35. Phase 2 trial of oral S-1 combined with low-dose cisplatin for unresectable advanced pancreatic cancer.
    Ina S, Tani M, Kawai M, Hirono S, Miyazawa M, Nishioka R, Fujita Y, Yamaue H.
    Anticancer Res; 2008 Nov 20; 28(4C):2373-7. PubMed ID: 18751421
    [Abstract] [Full Text] [Related]

  • 36. Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer.
    Ozawa Y, Inui N, Naitoh T, Yasuda K, Nagayama M, Shirai T, Suganuma H, Fujii M, Nakamura H, Suda T, Chida K.
    Lung Cancer; 2009 Jan 20; 63(1):68-71. PubMed ID: 18513824
    [Abstract] [Full Text] [Related]

  • 37. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.
    Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB.
    Clin Cancer Res; 2008 Jul 01; 14(13):4225-31. PubMed ID: 18594004
    [Abstract] [Full Text] [Related]

  • 38. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.
    Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J.
    Eur J Cancer; 2009 May 01; 45(8):1415-23. PubMed ID: 19168349
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
    Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, Kim MK, Lee KH, Hyun MS, Lee WS, Sohn CH, Jung JS, Kim GC, Chung HY, Yu W.
    Cancer Chemother Pharmacol; 2009 Jul 01; 64(2):355-60. PubMed ID: 19052714
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.